{"doi":"10.1007/s00277-026-06956-8","title":"Outcomes of pediatric and adult patients with relapsed/refractory cortical (CD1a+) T-cell acute lymphoblastic leukemia. The Spanish experience from SEHOP and PETHEMA groups","abstract":"<jats:title>Abstract</jats:title>\n                  <jats:p>Patients with relapsed/refractory T-cell acute lymphoblastic leukemia (R/R T-ALL) have very poor prognosis. CAR T-cell therapy is being explored in these patients with encouraging results. Specifically, CD1a-directed CAR T-cells are being explored in clinical trials to treat cortical T-ALL (CD1a+), but there are no data on outcome in this subgroup of patients before this therapy. This retrospective, observational study aimed to describe the characteristics and outcomes of patients with R/R CD1a + T-ALL. We included pediatric and adult patients diagnosed with R/R CD1a + T-ALL in 25 sites of Spain between March 2006 and May 2022. The primary outcome of the study was overall survival (OS). Forty-three patients, 28 adults and 15 children, with R/R CD1a + T-ALL were included. Median (range) age at inclusion was 24 years (5–57), and 82.5% were male. After a median (range) follow-up of 7.0 years (5.1–13.6), 6 (14.0%) patients were alive and in complete remission (CR) and 37 (86.0%) had died. Five-year OS was 16% (95% CI; 7–29%). Bone marrow relapse, an interval &lt; 12 months between first CR and relapse, and lack of allogeneic hematopoietic stem cell transplantation during salvage treatment were associated with worse OS. Our results confirm that patients with R/R CD1a + T-ALL have a very poor prognosis, highlighting the need for new treatment alternatives in these patients.</jats:p>","journal":"Annals of Hematology","year":2026,"id":641637,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1668433,"name":"Mireia Morgades","orcid":null,"position":1,"is_corresponding":false},{"id":1668434,"name":"Anna Alonso-Saladrigues","orcid":null,"position":2,"is_corresponding":false},{"id":284250,"name":"Pau Montesinos","orcid":"0000-0002-3275-5593","position":3,"is_corresponding":false},{"id":1668435,"name":"Thais Murciano","orcid":null,"position":4,"is_corresponding":false},{"id":845739,"name":"Cristina Gil","orcid":"0000-0001-7296-3445","position":5,"is_corresponding":false},{"id":1668436,"name":"Rosa Adán","orcid":null,"position":6,"is_corresponding":false},{"id":1031898,"name":"Jordi Esteve","orcid":"0000-0002-8056-648X","position":7,"is_corresponding":false},{"id":1420524,"name":"Carolina Fuentes","orcid":null,"position":8,"is_corresponding":false},{"id":1668437,"name":"María Luz Amigo","orcid":null,"position":9,"is_corresponding":false},{"id":1668438,"name":"Berta González-Martínez","orcid":null,"position":10,"is_corresponding":false},{"id":1668439,"name":"Rosa Coll","orcid":null,"position":11,"is_corresponding":false},{"id":1668440,"name":"José Luis Dapena","orcid":null,"position":12,"is_corresponding":false},{"id":1668442,"name":"María Paz Queipo de Llano","orcid":null,"position":13,"is_corresponding":false},{"id":1668444,"name":"José Luis Fuster","orcid":null,"position":14,"is_corresponding":false},{"id":1585168,"name":"Irene García-Cadenas","orcid":null,"position":15,"is_corresponding":false},{"id":1668445,"name":"María Tasso","orcid":null,"position":16,"is_corresponding":false},{"id":669491,"name":"Pere Barba","orcid":"0000-0003-1038-5197","position":17,"is_corresponding":false},{"id":1195429,"name":"Susana Rives","orcid":"0000-0002-5658-1831","position":18,"is_corresponding":false},{"id":1668448,"name":"Josep Maria Ribera","orcid":null,"position":19,"is_corresponding":false},{"id":1668432,"name":"Cristina Rivera-Pérez","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Outcomes of pediatric and adult patients with relapsed/refractory cortical (CD1a+) T-cell acute lymphoblastic leukemia. The Spanish experience from SEHOP and PETHEMA groups","abstract":"<jats:title>Abstract</jats:title>\n                  <jats:p>Patients with relapsed/refractory T-cell acute lymphoblastic leukemia (R/R T-ALL) have very poor prognosis. CAR T-cell therapy is being explored in these patients with encouraging results. Specifically, CD1a-directed CAR T-cells are being explored in clinical trials to treat cortical T-ALL (CD1a+), but there are no data on outcome in this subgroup of patients before this therapy. This retrospective, observational study aimed to describe the characteristics and outcomes of patients with R/R CD1a + T-ALL. We included pediatric and adult patients diagnosed with R/R CD1a + T-ALL in 25 sites of Spain between March 2006 and May 2022. The primary outcome of the study was overall survival (OS). Forty-three patients, 28 adults and 15 children, with R/R CD1a + T-ALL were included. Median (range) age at inclusion was 24 years (5–57), and 82.5% were male. After a median (range) follow-up of 7.0 years (5.1–13.6), 6 (14.0%) patients were alive and in complete remission (CR) and 37 (86.0%) had died. Five-year OS was 16% (95% CI; 7–29%). Bone marrow relapse, an interval &lt; 12 months between first CR and relapse, and lack of allogeneic hematopoietic stem cell transplantation during salvage treatment were associated with worse OS. Our results confirm that patients with R/R CD1a + T-ALL have a very poor prognosis, highlighting the need for new treatment alternatives in these patients.</jats:p>","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"41874722","pmcid":"PMC13013216","openalex_id":"https://openalex.org/W7140164125","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.28684374,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://link.springer.com/content/pdf/10.1007/s00277-026-06956-8.pdf","host_type":"journal"},{"url":"https://link.springer.com/content/pdf/10.1007/s00277-026-06956-8.pdf","host_type":"publisher"},{"url":"https://link.springer.com/article/10.1007/s00277-026-06956-8","host_type":"publisher"},{"url":"https://doi.org/10.1007/s00277-026-06956-8","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/41874722","host_type":"repository"},{"url":"https://doaj.org/article/20d164cf58d5481a81619f1d4d990fca","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13013216/","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC13013216","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC13013216?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Acute Lymphoblastic Leukemia research","CAR-T cell therapy research","Lymphoma Diagnosis and Treatment","Humans","Male","Adult","Precursor T-Cell Lymphoblastic Leukemia-Lymphoma","Female","Retrospective Studies","Adolescent","Child","Spain","Middle Aged","Young Adult","Child, Preschool","Antigens, CD1","Recurrence","Treatment Outcome","Immunotherapy, Adoptive","Follow-Up Studies"],"mesh_terms":["Adolescent","Adult","Child","Child, Preschool","Female","Follow-Up Studies","Humans","Male","Middle Aged","Recurrence","Retrospective Studies","Spain","Immunotherapy, Adoptive","Treatment Outcome","Antigens, CD1","Precursor T-Cell Lymphoblastic Leukemia-Lymphoma","Young Adult"],"keywords":["Observational study","Hematology","Lymphoblastic Leukemia","Hematopoietic stem cell transplantation","Bone marrow","Transplantation","Pediatric oncology","Clinical trial","Acute lymphocytic leukemia","Survival","Immunotherapy","Cd1a Antigen","Relapsed/refractory T-cell Acute Lymphoblastic Leukemia (R/r T-all)"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"eudract"},{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T19:23:17.867020Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}